Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

Trial Details

NCT ID
NCT07805954
Phase
PHASE3
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • daraxonrasib
  • gemcitabine
  • nab-paclitaxel
  • zoldonrasib
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Tampa, Florida, United States|27.94752,-82.45843
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advan…
  • No prior treatment in the locally advanced unresectable or metastatic setting

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →